NO944916L - Fremgangsmåte for å inhibere fertilitet hos kvinner - Google Patents

Fremgangsmåte for å inhibere fertilitet hos kvinner

Info

Publication number
NO944916L
NO944916L NO944916A NO944916A NO944916L NO 944916 L NO944916 L NO 944916L NO 944916 A NO944916 A NO 944916A NO 944916 A NO944916 A NO 944916A NO 944916 L NO944916 L NO 944916L
Authority
NO
Norway
Prior art keywords
women
inhibiting fertility
fertility
inhibiting
woman
Prior art date
Application number
NO944916A
Other languages
English (en)
Other versions
NO944916D0 (no
Inventor
Charles David Jones
Frank C Nmn Tinsley
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944916D0 publication Critical patent/NO944916D0/no
Publication of NO944916L publication Critical patent/NO944916L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det er beskrevet en fremgangsmåte for å inhibere fertilitet hos kvinner som Innbefatter administrering til en kvinne av en effektiv mengde av en forbindelse som har formelen (I) og farmasøytisk akseptable salter og solvater derav.
NO944916A 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere fertilitet hos kvinner NO944916L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/170,945 US5462949A (en) 1993-12-21 1993-12-21 Methods of inhibiting fertility in women

Publications (2)

Publication Number Publication Date
NO944916D0 NO944916D0 (no) 1994-12-19
NO944916L true NO944916L (no) 1995-06-22

Family

ID=22621919

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944916A NO944916L (no) 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere fertilitet hos kvinner

Country Status (15)

Country Link
US (1) US5462949A (no)
EP (1) EP0659429A1 (no)
JP (1) JPH07215870A (no)
KR (1) KR950016747A (no)
CN (1) CN1108091A (no)
AU (1) AU8154594A (no)
CA (1) CA2138456A1 (no)
CZ (1) CZ322994A3 (no)
HU (1) HUT71328A (no)
IL (1) IL112030A (no)
NO (1) NO944916L (no)
NZ (1) NZ270188A (no)
PH (1) PH31268A (no)
RU (1) RU94044438A (no)
ZA (1) ZA9410099B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2162586C (en) 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5569459A (en) * 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US20020169205A1 (en) * 1998-09-29 2002-11-14 Krzysztof Chwalisz Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
IL65379A0 (en) * 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
JPH07215870A (ja) 1995-08-15
CN1108091A (zh) 1995-09-13
HU9403678D0 (en) 1995-02-28
HUT71328A (en) 1995-11-28
IL112030A0 (en) 1995-03-15
NZ270188A (en) 1997-01-29
IL112030A (en) 1998-03-10
AU8154594A (en) 1995-06-29
RU94044438A (ru) 1996-10-20
PH31268A (en) 1998-06-18
EP0659429A1 (en) 1995-06-28
ZA9410099B (en) 1996-06-19
CZ322994A3 (en) 1995-08-16
US5462949A (en) 1995-10-31
CA2138456A1 (en) 1995-06-22
NO944916D0 (no) 1994-12-19
KR950016747A (ko) 1995-07-20

Similar Documents

Publication Publication Date Title
NO944916L (no) Fremgangsmåte for å inhibere fertilitet hos kvinner
DE69608904T2 (de) Nicht-steroidale sulfatase hemmer verbindungen
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
UA32427C2 (uk) Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944929L (no) Fremgangsmåte for å inhibere CNS-problemer i post-menopausale kvinner
DE69421694D1 (en) Interleukin-1 inhibitor
MX9709466A (es) Medicamento para inhibir el melanoma.
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO944920D0 (no) Fremgangsmåte for å inhibere hirsutisme og alopecia hos kvinner
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
NO970787L (no) Fremgangsmåte for hemming av primær endometrial hyperplasi
DK0772438T3 (da) Anvendelse af benzothiophener til fremstilling af et medikament til reduktion af ardannelse under sårheling
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9706520A (es) Metodos para inhibir el cancer de ovario.
MX9702853A (es) Metodos para inhibir condiciones asociadas con el neuropeptido "y".
NO973470L (no) Fremgangsmåte for minsking av serumkalsiumnivåer